Exact Sciences price target lowered to $75 from $95 at Canaccord
The Fly

Exact Sciences price target lowered to $75 from $95 at Canaccord

Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $95 and keeps a Buy rating on the shares. Although the company’s Q3 results and reduction to 2024 guidance “are a touch alarming,” Canaccord remains bullish on Exact’s long-term growth potential, the analyst tells investors in a research note. The firm says the company’s financial performance was negatively impacted by multiple factors in Q3, including muted sales force productivity and slow transition of the Precision Oncology test portfolio to the Exact Nexus platform. It remains constructive on the shares, recognizing that it maintains modestly less conviction in Exact’s ability to drive consistent growth in its important Cologuard business.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App